GlaxoSmithKline Pharmaceuticals · NSE: GLAXO · BSE: 500660
Q4 FY19 results · Jan–Mar 2019
GlaxoSmithKline Pharmaceuticals reported revenue from operations of ₹0.00 crore and net profit of ₹0.00 crore for Q4 FY19 (Jan–Mar 2019), on a consolidated basis.
| Item | Q4 FY19 | Q4 FY18 | YoY | Q3 FY19 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 0.00 | — | — | — | — |
| Other income | 0.00 | — | — | — | — |
| Total income | 0.00 | — | — | — | — |
| Profit before tax | 0.00 | — | — | — | — |
| Net profit for the period | 0.00 | — | — | — | — |
| EPS, basic (₹) | 0.00 | — | — | — | — |
| Net margin (%) | — | — | — |
| Item | Q4 FY19 | Q4 FY18 | YoY | Q3 FY19 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 751.22 | — | — | 825.35 | −9.0% |
| Other income | 52.46 | — | — | 16.42 | +219.5% |
| Total income | 803.68 | — | — | 841.77 | −4.5% |
| Profit before tax | 199.16 | — | — | 169.78 | +17.3% |
| Net profit for the period | 123.03 | — | — | 112.97 | +8.9% |
| EPS, basic (₹) | 7.26 | — | — | 6.67 | +8.9% |
| Net margin (%) | 16.4 | — | 13.7 |
Consolidated
- Filed with BSE
- 20 May 2019, 18:34 IST
- Board meeting
- 20 May 2019
- Period
- 01 Jan 2019 to 31 Mar 2019
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 20 May 2019, 18:31 IST
- Board meeting
- 20 May 2019
- Period
- 01 Jan 2019 to 31 Mar 2019
- Review status
- Audited
- Source
- XBRL filing on BSE